ArticleCureus2025
Unveiling the Interconnected Dynamics of Mitochondrial Dysfunction Associated With Age-Related Cardiovascular Risk: A Cross-Sectional Pilot Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Higher mitochondrial DNA methylation is associated with increased risk of stroke: a nested case-control study.Human genetics · 2026Article
- Mitochondrial Epigenetic Alterations Induced by Biomass Smoke Exposure and Their Role in Age-Related Breast Cancer Risk: A Machine Learning-Based Predictive Study.Asian Pacific journal of cancer prevention : APJCP · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging, influenced by complex epigenetic mechanisms, significantly contributes to the progression of cardiovascular diseases (CVDs). This cross-sectional pilot study investigated mitochondrial-associated epigenetic stress responses in two age groups: Group I (18-38, n = 154), representing younger adults generally at lower risk for CVD, and Group II (39-65, n = 105), representing middle-aged and older adults with increased biological susceptibility. The age grouping was based on established physiological and cardiovascular risk transitions typically observed around age 40. To assess age-related molecular variations, we examined key mitochondrial and metabolic parameters, including mitochondrial DNA (mtDNA) damage repair capacity, mtDNA copy number (mtDNAcn), methylation status, mitochondrial dynamics (fusion/fission), telomere length, expression of respiratory complex genes, levels of pro-inflammatory cytokines, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. Our results indicated that the older group exhibited higher mtDNA methylation (r² = 0.5205, p < 0.0001), increased mtDNAcn, and elevated NT-proBNP levels, which also showed a weak positive correlation with mtDNA methylation (r² = 0.3218, p < 0.0001). Additionally, a strong negative correlation was observed between telomerase reverse transcriptase (TERT) expression and age (r² = 0.6070, p < 0.0001), suggesting a decline in telomeric maintenance with advancing age. Group II also showed altered inflammatory and telomeric profiles and a notable reduction in the expression of mitochondrial respiratory complex genes (ND6, COXI, ATPase 6 and 8), alongside increased expression of genes involved in mitochondrial stress response pathways. We employed four machine learning models - Logistic Regression, Decision Tree, Random Forest, and Support Vector Machine (SVM) - for CVD risk prediction, using selected mitochondrial and metabolic features. All models demonstrated high classification accuracy, ranging from 0.920 to 1.0, with the Random Forest model achieving the highest accuracy of 0.984. These preliminary findings highlight distinct age-related molecular signatures and illustrate the potential of combining biomarkers with machine-learning approaches to improve cardiovascular risk prediction and therapeutic targeting in aging populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.